Acurx Pharmaceuticals, LLC (“Acurx” or the “Company”), a privately held, clinical stage, biopharmaceutical company developing new antibiotics for difficult-to-treat bacterial infections, announced today that it will present the Phase 1 clinical trial results for its lead antibiotic candidate, ACX-362E, under development for the oral treatment of patients with C. difficile Infection (CDI).
November 4, 2019
· 8 min read